These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8403299)

  • 1. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
    Peerlinck K; De Lepeleire I; Goldberg M; Farrell D; Barrett J; Hand E; Panebianco D; Deckmyn H; Vermylen J; Arnout J
    Circulation; 1993 Oct; 88(4 Pt 1):1512-7. PubMed ID: 8403299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men.
    Barrett JS; Murphy G; Peerlinck K; De Lepeleire I; Gould RJ; Panebianco D; Hand E; Deckmyn H; Vermylen J; Arnout J
    Clin Pharmacol Ther; 1994 Oct; 56(4):377-88. PubMed ID: 7955799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
    Kereiakes DJ; Kleiman NS; Ambrose J; Cohen M; Rodriguez S; Palabrica T; Herrmann HC; Sutton JM; Weaver WD; McKee DB; Fitzpatrick V; Sax FL
    J Am Coll Cardiol; 1996 Mar; 27(3):536-42. PubMed ID: 8606262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ; Cook JJ; Sitko GR; Holahan MA; Ramjit DR; Mellott MJ; Stranieri MT; Stabilito II; Zhang G; Lynch RJ
    J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
    Umemura K; Kondo K; Ikeda Y; Nakashima M
    Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
    Reiter RA; Mayr F; Blazicek H; Galehr E; Jilma-Stohlawetz P; Domanovits H; Jilma B
    Blood; 2003 Dec; 102(13):4594-9. PubMed ID: 12920042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2001 Aug; 142(2):204-10. PubMed ID: 11479455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
    Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
    Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
    Müller TH; Weisenberger H; Brickl R; Narjes H; Himmelsbach F; Krause J
    Circulation; 1997 Aug; 96(4):1130-8. PubMed ID: 9286940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers.
    Greenberg HE; Wissel P; Barrett J; Barchowsky A; Gould R; Farrell D; Panebianco D; Hand E; Gillen L; Goldberg MR; Bjornsson TD
    J Clin Pharmacol; 2000 May; 40(5):496-507. PubMed ID: 10806603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs.
    Mousa SA; Flint S; Lorelli W; Hassell S; Bozarth J; De Grado W; Reilly TM
    Thromb Res; 1994 Oct; 76(2):109-19. PubMed ID: 7863463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study.
    Théroux P; Kouz S; Roy L; Knudtson ML; Diodati JG; Marquis JF; Nasmith J; Fung AY; Boudreault JR; Delage F; Dupuis R; Kells C; Bokslag M; Steiner B; Rapold HJ
    Circulation; 1996 Sep; 94(5):899-905. PubMed ID: 8790023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
    Egbertson MS; Chang CT; Duggan ME; Gould RJ; Halczenko W; Hartman GD; Laswell WL; Lynch JJ; Lynch RJ; Manno PD
    J Med Chem; 1994 Aug; 37(16):2537-51. PubMed ID: 8057299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J; Rebello SS; Faul JD; Lucchesi BR
    Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.